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I In nt tr ro od du uc ct ti io on n
Microsatellite Instability testing (MSI) is not germline
genetic testing. A high level of microsatellite instability
(MSI-H) is a tumour phenotype that is known to be
associated with defective function of tumour DNA
mismatch repair (MMR). The MSI-H tumour phenotype
is present in about 15-20% of all colorectal cancers
(CRC) and in nearly all CRC from individuals with
Hereditary Non Polyposis Colon Cancer (HNPCC) who
carry germline mutations in DNA MMR genes [1-3]. 
Tumour MSI phenotyping is conducted both clinically
and in research settings primarily to identify individuals
who  may  have  the  autosomal  dominant  disorder,
Hereditary Non Polyposis Colon Cancer Syndrome
(HNPCC or Lynch Syndrome). In individuals with this
disorder that carry germline mutations in the DNA MMR
genes, nearly all tumours show the MSI-H phenotype [4].
Thus a negative MSI test fairly well excludes a diagnosis
of HNPCC due to hereditary DNA mismatch repair
mutations. No work has been done on the interest, effect,
adequacy, or appropriateness of communication of
A Ab bs st tr ra ac ct t
P Pu ur rp po os se e: : To determine which individuals with colorectal cancer (CRC) were interested in knowing the results of their
tumour microsatellite instability (MSI) and immunohistochemistry (IHC) testing. We were also interested in the patients’
reasons for choosing to learn their results and in the impact of those results on overall self-assessed quality of life. 
P Pa at ti ie en nt ts s   a an nd d   M Me et th ho od ds s: :   CRCs from 414 individuals were assayed for MSI and IHC for DNA mismatch repair
gene products (MLH1, MSH2, MSH6). Individuals were invited to learn their MSI/IHC results. They randomly
received either brief or extended educational materials about the testing and a pretest survey to learn reasons
for their interest and to assess their pretest quality of life. 
R Re es su ul lt ts s: : Of the 414 individuals, 307 (74%) chose to learn their results. There was no significant difference in
interest in knowing test results according to gender, age, educational level, or family history of colon cancer. The
level of detail in the information piece received by the patients did not influence their desire to know their test
results. Self-assessed quality of life was not altered by receiving results and was not correlated with the test outcome. 
C Co on nc cl lu us si io on ns s: : Individuals with colorectal cancer had a high level of interest in learning their individual MSI/IHC
test results and did not seem deterred by the inherent complexity or ambiguity of this information. Regardless
of test outcome, results did not significantly affect self-assessed quality of life. Further studies are needed to
assess comprehension of results and behavioural changes resulting from the learning of MSI/IHC results. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 70
tumour MSI phenotyping results to patients. Do patients
want to know their MSI results? Which patients? Why? 
The MSI/IHC story is more complex than just
a negative or a positive result. In any series of colon
cancers not preselected for high risk features (i.e.,
young age at diagnosis or multiple affected family
members), tumour MSI-H will be present in about 15-
20% of cases [4-6]. In these series, an MSI-H tumour
phenotype does not necessarily indicate increased
hereditary risks to relatives; in this situation, the defective
DNA mismatch repair is usually secondary to somatic
hypermethylation of the hMLH1 promoter. IHC in this
setting will show loss of expression of hMLH1 [7, 8],
(Kim 2003) but this occurrence does not have a clear
Mendelian hereditary component. Thus a ”positive” test
(MSI-H tumour) is not diagnostic for HNPCC. In fact,
among all patients with colon cancer, most MSI-H results
are not due to HNPCC but are due to age-related
methylation of the hMLH1 gene [2, 9, 10]. Therefore,
unlike germline genetic testing for HNPCC where
a positive result is diagnostic of a hereditary disorder,
tumour phenotyping can only conclude that a person
might have a hereditary disorder, but a positive test is
not diagnostic for a hereditary disorder. 
The MSI-H phenotype is the gold standard for
determining MMR competency in the tumour. Defective
MMR in a tumour can be due to one of five known
genes and perhaps more [11]. Immunohistochemistry
staining is often done as a complementary test to MSI,
as loss of expression of one of the MMR genes indicates
which specific gene is not functioning properly, thereby
causing the MSI phenotype [12]. Since direct DNA
genetic testing is expensive and has only about 70%
sensitivity in detecting mutations, tumour MSI/IHC testing
has become the preferred first step in screening for MMR
status of a given tumour; it is the starting point for trying
to pick out individuals who may have HNPCC. A positive
MSI test in a high-risk setting can identify those who
should be offered germline genetic testing, and IHC loss
of expression pinpoints which gene should be studied. 
We expect that in coming years clinical phenotyping
of colon cancers will gain a second purpose, as early data
suggest different responses to certain chemotherapies in
individuals with MSI-H tumours. However, this preliminary
information is unconfirmed and conflicting and does not
yet impact clinical oncologic decision-making. Therefore,
the current clinical utility of MSI/IHC testing is limited to
identification of individuals who might have HNPCC, as
this drastically effects screening recommendations and
opens up options for germline genetic testing (which was
NOT the topic of this study). 
As part of an ongoing colon cancer study, tumour
phenotyping was conducted on tumour specimens from
study participants. Because the results contained some
potentially clinically significant information for some
participants, we concluded that results should be returned
to all individuals. As is evident from the opening
paragraphs, explaining tumour MSI phenotyping and
interpreting individual results is a challenge. We sought
to learn what we could about which patients opted to
learn their results, to determine what reasons they had
for deciding to learn results, to determine the effect of
detail (an in-depth explanation of testing versus a brief
overview), and to assess global psychological reactions
to being offered and receiving these complex test results
via a written communication. 
M Me et th ho od ds s
The study scheme is shown in Figure 1. Ascertained
through the Mayo Clinic to the IRB-approved Cooperative
Family Registry for Colorectal Cancer Studies (Colon
CFR), 414 patients with colorectal tumours and signed
informed consent were included in this study. The Colon
CFR is an NCI-supported consortium established in 1997,
of which the Mayo CFR is one member. The Colon CFR
was established to develop a comprehensive collaborative
infrastructure for interdisciplinary studies in the genetics
and genetic epidemiology of colorectal cancer. Detailed
information about the Colon CFR can be found at
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Follow-up phone call to MSI-H
participants 3 months after results
sent to answer any questions and to
be sure the results were received
No contact No contact
No further contact
Y Ye es s n=307    N No o n=24 N No o   r re es sp po on ns se e n=83
Pilot letter to offer MSI/IHC results sent to 40 study participants,
and asking if they would agree to phone interview. 
No Yes
PI/Co-I conducted telephone interview with this pilot group 
to assist in finalizing questionnaire options
414 CRC cases invited by mail to learn MSI/IHC results;
randomized to get short or long educational piece with first
mailing; questionnaire about decision making included
Send MSI result
Send other
educational piece
Send f/u
questionnaire
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Mayo CFR consent form stated that if a clinically useful
result  was  generated  in  the  course  of  this  study,
participants would be given the option of learning those
results. Participants understood that their data and
materials would be used for colon cancer research, but
the exact nature of studies to be conducted was not
specified in the consent form as this registry is designed
to support a great number of studies of diverse types
for many years. 
The Mayo CFR participants were recruited from three
different sources: the Minnesota Cancer Surveillance
System (MCSS: a population-based registry), the North
Central Cancer Treatment Group, and Mayo Clinic
Rochester. All individuals who were under 50 years old
at the time of their colorectal cancer diagnosis as well
as individuals who reported a family history of colon
cancer were invited to enrol in the Colon CFR. In
addition, a random sampling of the MCSS listing was
also invited to enrol in the colon CFR. Thus, our patient
population was over-sampled for individuals who were
at higher risk for having HNPCC, but also included
subjects who were not at high risk for HNPCC. The
exact number of true HNPCC participants in this group
has not yet been determined. After consenting CFR
participants to this registry, a three-generation family
history was obtained, a detailed risk factor questionnaire
was completed, blood specimens were collected and
we asked for release of tumour blocks, if available, for
additional studies. Participants were not specifically
informed that tumour MSI testing or any other specific
laboratory test was planned although they consented
to use of their biospecimens and data for cancer-related
research projects. 
Tumour microsatellite instability (MSI) testing and
tumour  immunohistochemistry  (IHC)  staining  for
hMLH1, hMSH2, and hMSH6 protein products were
conducted as we have previously described [12]. 
We developed a patient contact letter offering
individuals the results of their tumour MSI/IHC testing.
This letter went to all study participants on whom MSI
testing  was  completed.  We  also  developed  two
conceptually different educational pieces as we had no
way  to  know  in  advance  the  optimal  way  to
communicate results of this complexity and ambiguity.
One educational piece was a six-page explanation of
tumour MSI/IHC testing and its possible implications.
The other was a one-page overview of MSI/IHC testing
entitled, ”Get to the Point, Doc”, subtitled ”For people
who just want the bottom line”. (These are available
upon request). Patients were randomized (unstratified)
to receive either the long or the short educational piece
in the initial mailing. 
We also developed a survey to be self-administered
before results were received to learn people’s reasons
for choosing whether or not to see their results and also
to rate their current quality of life on a simple one item
0-10 scale. The Linear Analogue Self Assessment (LASA)
items have been validated as general measures of global
QOL dimensional constructs in numerous settings [13-
17]. A series of five LASA items have been constructed
and validated at Mayo for use in cancer patients [18]. 
For those who responded that they would like to
receive their results, letters were composed that showed
their  MSI/IHC  results  with  a limited  amount  of
interpretive text and, when appropriate, information on
how to obtain individualized genetic consultation.
(Genetic counselling was not funded through this study.)
At the time the results were relayed, all participants
received the educational piece that they had not gotten
in the original mailing. Thus, all participants ultimately
were exposed to both the long and the short educational
pieces to assure that everyone received everything we
could offer. We then surveyed again for quality of life
on the single item 0-10 point scale and comfort level
(again a 0-10 scale) with their decision regarding
receiving their test results. In addition, we made one
follow-up  phone  call  to  inquire  about  subjective
preferences for the long versus short educational
explanations of MSI/IHC testing and to be certain that
study participants had a chance to voice concerns, ask
questions or clarifications, or to ask for re-mailings. 
R Re es su ul lt ts s
W Wh ho o  w wa an nt te ed d  t th he ei ir r  M MS SI I/ /I IH HC C  r re es su ul lt t? ?  
A total of 414 patients participated in this study,
including 209 men and 205 women. Twenty-two
percent had MSI-H tumours. Three hundred and seven
(307) individuals (74%) responded that they did want
their results, and 107 either declined their results
(n=24) or simply never responded at all (n=83). We
were not able to survey the reasons for declining or not
responding to our letter although we could describe
the demographics of this group as shown below. 
There was no significant difference between men
and women in their interest in knowing their tumour
MSI results: 72% versus 77% (p>0.10). 
The majority of people of all ages wanted to know
their MSI result. We found that 74% of patients under
the age of 50 wanted results compared to 81%,
76.5%, and 63% at ages 50-59, 60-69, and over 70
years, respectively. 
We evaluated the influence that formal education
might have on one’s desire for MSI test results. In soH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 72
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W Wh ho o   C Ch ho os se e   t to o   R Re ec ce ei iv ve e   M MS SI I   R Re es su ul lt ts s
Overall
Overall
Sex
Age
Education
Family history (# 1st/2nd degree relative with CRC)
% Choosing to Receive Their MSI Results
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doing, we compared the preference regarding knowing
MSI results in those with up to 1 year of post high
school technical school with those with one or more
years of college. The majority of both groups, 70%
versus 77% (p>0.11), wanted to know their results. 
Family history was also not a determinant of most
patients’ preference. For those with no first or second
degree relatives with colorectal cancer, 75% wanted
results, compared to 72% in those with one affected first
degree relative and 74% in those with more than one
first or second degree relative (p>0.10). We also
assessed whether or not having children influenced desire
to learn MSI/IHC results, but there was no significant
difference between responders and non-responders
according to having offspring. Figure 2 summarises the
analysis of who wanted MSI/IHC results. 
E Ef ff fe ec ct t  o of f  d de et ta ai il l  i in n  i in ni it ti ia al l  e ed du uc ca at ti io on na al l  o of ff fe er ri in ng g
We  determined  that  the  randomly  selected
educational provision, whether long or short, did not
affect interest in receiving MSI results. Of those who
did not respond, 57 received the short piece and 50
received the long piece (p>0.51). 
W Wh hy y  p pe eo op pl le e  w wa an nt te ed d  t th he ei ir r  M MS SI I  r re es su ul lt ts s
The participants were asked to rate eight potential
motivators on a 0-10 scale, where 0 indicated it was
not a factor at all, and 10 indicated it was an extremely
strong motivator. The results are shown in Figure 3. The
greatest motivators appeared to be ”helps understand
future family risk”, ”helps me make good choices”,
”wanting all the information I can get”, and ”contribute
to research”. We also attempted to survey those who
declined results; however, only four of the 107 returned
the survey, so meaningful analysis was not possible. 
C Ch ha an ng ge es s  i in n  s se el lf f- -r re ep po or rt te ed d  q qu ua al li it ty y  o of f  l li if fe e  a af ft te er r  g ge et tt ti in ng g  M MS SI I  r re es su ul lt t
After test results were sent out to all interested
participants, we compared their overall self-assessed
quality of life (QOL) before getting results to the quality
of life after receiving results. They had ranked their QOL
on a single item 0-10 scale, in which 0 was described as
”not at all happy with quality of life now”, and 10 was
described as ”very happy with quality of life right now”.
One hundred thirty four (68 men and 68 women) of the
307 participants who got the MSI results completed the
QOL scale before and after they knew their results.
Among men who got a ”normal” result (no MSI in their
tumour; n=54), there appeared to be a slight decrease
in QOL rating (but not statistically significant; p=0.62),
whereas women (n=53) with normal results showed no
change at all in their self-rating (p=0.99). 
In the group that got the ”abnormal” results (the
ambiguous  result  of  MSI-H  tumour  with  various
immunohistochemistry results), men (n=14) appeared
to show a slight improvement in QOL, though not
statistically significant (p=0.53) while women (n=13)
showed a slight trend toward decrease in self-rated
QOL (p=0.19), but again, not statistically significant. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 73
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We analysed the QOL ratings broken down by
educational level. Fifty four participants had less than
one year of post high school education, and 72 had
one or more years of college education. Educational
level did not correlate with overall change in QOL in
either group regardless of their MSI results. 
We analysed the self-reported change in QOL
stratified by age and found there was no significant
change in QOL in any age group no matter what the
MSI results were. We looked closely to see if even
a slight trend toward a change in QOL was emerging,
but receiving MSI results of any type seemed to be
a neutral event with respect to QOL. 
D Di is sc cu us ss si io on n
MSI/IHC testing has made its way into clinical
practice without any discussion whatsoever in the
medical  literature  regarding  whether  or  how  to
communicate its meaning to patients. Within the genetic
counselling community, some consider MSI testing to
be  included  under  the  genetic  testing  umbrella.
However, this seems an inaccurate assignment, since
no type of MSI/IHC test result can distinguish hereditary
disease  from  non-hereditary  disease.  MSI/IHC  is
a sophisticated and clinically useful triaging instrument
for which there is no analogous test, i.e., a test that is
very good at ruling out one form of hereditary disease
(hereditary DNA mismatch repair deficiency/HNPCC)
yet is incapable of establishing the diagnosis of that
same disease. An MSI-high test result means it is
possible that one has a hereditary disease, but further
testing (germline genetic mutation detection), integrated
with clinical data and family history, is necessary to
assign medical significance to an MSI-high result. 
Given the complexity and ambiguity of MSI/IHC
results, we were not sure if patients would be interested
in learning their result. We learned that three-quarters
of all patients enrolled in the Colon CFR were interested
in getting their results. When we sought to find out if
the sort of explanation provided of MSI (detailed versus
brief) would influence test uptake by patients, we were
unable to identify a preference for detailed versus brief
educational explanations and follow-up phone interview
did not elicit any preferences. We were also interested
to see if participants’ interest in receiving test results was
affected at all by differences in gender, age, education
level, and family history of colon cancer. With the
information gathered in this study, we could not identify
a subset of patients that was different from the whole.
As the final question explored in this study, we found
that test results generally did not adversely affect self-
assessed quality of life as measured in this study,
regardless of the test result. 
The level of overall interest in receiving MSI/IHC
results was higher, in our experience, than interest in
receiving research-based germline genetic test results.
In offering back germline test results in some family
cancer syndromes, only 25-33% of our invited study
participants responded that they wanted their result
(unpublished data). We speculate that the greater uptake
for the MSI results may be due in part to the fact that we
do not consider MSI/IHC testing to be genetic testing,
(a perspective put forth in our educational pieces).
Therefore, MSI/IHC test results may not have been felt
by patients to carry the same potential social stigma as
germline genetic test results. Similarly, because MSI/IHC
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testing is one step removed from diagnosing a hereditary
disease (it is a triage tool), there may be less psychological
trepidation about learning the result. It is important to
recognise that a second explanation for the high interest
in  receiving  these  results  may  be  that  Colon  CFR
participants are a selected group of individuals that are
particularly motivated and interested in research, as
shown by the fact that they did enrol in this registry in the
first place. 
People’s reasons for wanting their results were
multiple. While curiosity was a common motivator,
much more strongly endorsed reasons for wanting
MSI/IHC results were ”helps understand future family
risks”, ”helps me make good decisions”, ”want all the
information I can get”, and ”contribute to research”.
The least compelling reasons for wanting MSI/IHC
results were ”to compare to prior result” and ”asserting
my right to know”. 
While our study breaks new ground, its design had
several  important  limitations  which  need  full
acknowledgement. This study group is clearly not
representative of all colon cancer patients, noting that
the participants’ enrolment in the CFR study was
voluntary, indicating a level of cooperativity and interest
in supporting research studies. Further studies would
need to be conducted on colorectal cancer patients in
different settings to determine if interest in knowing
these results and reactions to learning results hold true
for different populations. Secondly, this group was not
ethnically  diverse  (98%  Caucasian).  Thirdly,  we
provided results in writing. While other research studies
may use this approach when individualized genetic
counselling is not feasible, it is likely that patients seen
clinically will have an opportunity to discuss MSI face
to face with their clinician, which may influence their
decision differently from our written materials. A fourth
limitation of this study is that we do not have long-term
follow up of reaction to knowledge of MSI results. In
addition, patients were not given a choice of receiving
their results in person, by phone, or some other
medium, so we have no point of comparison with
which to compare these study results. Lastly, and very
importantly,  we  do  not  know  if  patients  truly
comprehended the implications of their MSI/IHC results
and whether or not these results led to changes in
health care behaviours. Testing understanding of
material or factual retention or behavioural change
was not part of this study. Clearly there is much room
and need for further studies on the impact of MSI/IHC
testing in a variety of clinical and research settings. 
Umar et al recently published updated Bethesda
Guidelines defining the subset of colorectal cancer
patients on which MSI testing is recommended [19].
As this standard of care is adopted in clinical practice,
the  utilization  of  MSI/IHC  testing  will  increase
substantially. It is important to explore the ramifications
of this testing on the individuals being tested. 
In summary, we learned that there is a high level of
interest  among  all  types  of  colon  cancer  study
participants in the Colon CFR in learning individual
MSI/IHC test results, and providing individual results by
mail, accompanied by written educational pieces, was
acceptable to this group of patients and did not appear
to change their quality of life. This study is the first to
explore the issue of returning MSI/IHC results to patients.
Further studies on relaying MSI/IHC results to diverse
colon cancer populations are needed to further refine
patients’  needs  and  preferences  and  refining  the
educational methods for this communication. 
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